{"pmid":32435649,"pmcid":"PMC7218924","title":"Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics.","text":["Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics.","Front Med (Lausanne)","D'Marco, Luis","Puchades, Maria Jesus","Romero-Parra, Maria","Gorriz, Jose Luis","32435649"],"journal":"Front Med (Lausanne)","authors":["D'Marco, Luis","Puchades, Maria Jesus","Romero-Parra, Maria","Gorriz, Jose Luis"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435649","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fmed.2020.00199","keywords":["covid-19","cardiovascular disease","chronic kidney disease","diabetic kidney disease","renal damage"],"topics":["Prevention"],"weight":1,"_version_":1667521393831444480,"score":9.490897,"similar":[{"pmid":32448633,"title":"[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]","text":["[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]","The SARS-CoV-2 pandemic is a global health emergency and we need to know more about it. Patients with cardiovascular risk and previous kidney risk have been identified as especially vulnerable for greater morbidity and mortality when they suffer from COVID-19. A considerable proportion of patients can develop a vascular lesion in the context of the disease that entails a greater lethality. Cardiovascular and renal complications represent a problem and, probably in the near future, may pose a threat to patients who have survived COVID-19. As physicians, we cannot forget that during an epidemic like this, other chronic diseases are present, and patients continue to require care. We are obliged to monitor even more intensely their treatments and control degree. Furthermore, we must not forget that urgent situations continue to arise in this pandemic situation and require prompt attention. In this current situation, it is very likely that many patients, out of fear, have not sought medical attention. The situation during the epidemic and the uncertainty of the post-COVID-19 period, requires intensification in the control and monitoring of cardiovascular and kidney disease in our patients. Primary care constitutes a key level of care for the care of the population with cardiovascular disease. Likewise, and in the face of this new health scenario, we need to promote the prevention and control measures that emanate from the studies currently underway. Now, more than ever, we need research, crucial to improve the cardiovascular and renal prognosis of our patients.","Semergen","Pallares Carratala, V","Gorriz-Zambrano, C","Morillas Arino, C","Llisterri Caro, J L","Gorriz, J L","32448633"],"abstract":["The SARS-CoV-2 pandemic is a global health emergency and we need to know more about it. Patients with cardiovascular risk and previous kidney risk have been identified as especially vulnerable for greater morbidity and mortality when they suffer from COVID-19. A considerable proportion of patients can develop a vascular lesion in the context of the disease that entails a greater lethality. Cardiovascular and renal complications represent a problem and, probably in the near future, may pose a threat to patients who have survived COVID-19. As physicians, we cannot forget that during an epidemic like this, other chronic diseases are present, and patients continue to require care. We are obliged to monitor even more intensely their treatments and control degree. Furthermore, we must not forget that urgent situations continue to arise in this pandemic situation and require prompt attention. In this current situation, it is very likely that many patients, out of fear, have not sought medical attention. The situation during the epidemic and the uncertainty of the post-COVID-19 period, requires intensification in the control and monitoring of cardiovascular and kidney disease in our patients. Primary care constitutes a key level of care for the care of the population with cardiovascular disease. Likewise, and in the face of this new health scenario, we need to promote the prevention and control measures that emanate from the studies currently underway. Now, more than ever, we need research, crucial to improve the cardiovascular and renal prognosis of our patients."],"journal":"Semergen","authors":["Pallares Carratala, V","Gorriz-Zambrano, C","Morillas Arino, C","Llisterri Caro, J L","Gorriz, J L"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448633","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.semerg.2020.05.005","keywords":["covid-19","cardiovascular disease","chronic kidney disease","enfermedad cardiovascular","enfermedad renal cronica","morbidity","morbilidad","mortalidad","mortality"],"topics":["Prevention"],"weight":1,"_version_":1667785213894197248,"score":107.176926},{"pmid":32367746,"title":"ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective.","text":["ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective.","Potential but unconfirmed risk factors for coronavirus disease 2019 in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Coronavirus binding to angiotensin-converting enzyme 2, a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus but the reasons are unclear. This review will highlight the relationship of coronavirus disease 2019 with hypertension, use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the angiotensin-converting enzyme 2/angiotensin-(1-7) pathway in children and the clinical evidence for how angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers affect this important pathway. Given the importance of the angiotensin-converting enzyme 2/angiotensin-(1-7) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe coronavirus disease 2019.","Hypertension","South, Andrew M","Brady, Tammy M","Flynn, Joseph T","32367746"],"abstract":["Potential but unconfirmed risk factors for coronavirus disease 2019 in adults and children may include hypertension, cardiovascular disease, and chronic kidney disease, as well as the medications commonly prescribed for these conditions, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Coronavirus binding to angiotensin-converting enzyme 2, a crucial component of the renin-angiotensin-aldosterone system, underlies much of this concern. Children are uniquely impacted by the coronavirus but the reasons are unclear. This review will highlight the relationship of coronavirus disease 2019 with hypertension, use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, and lifetime risk of cardiovascular disease from the pediatric perspective. We briefly summarize the renin-angiotensin-aldosterone system and comprehensively review the literature pertaining to the angiotensin-converting enzyme 2/angiotensin-(1-7) pathway in children and the clinical evidence for how angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers affect this important pathway. Given the importance of the angiotensin-converting enzyme 2/angiotensin-(1-7) pathway and the potential differences between adults and children, it is crucial that children are included in coronavirus-related research, as this may shed light on potential mechanisms for why children are at decreased risk of severe coronavirus disease 2019."],"journal":"Hypertension","authors":["South, Andrew M","Brady, Tammy M","Flynn, Joseph T"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367746","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1161/HYPERTENSIONAHA.120.15291","keywords":["angiotensin-(1-7)","cardiovascular disease","chronic kidney disease","coronavirus","sars-cov-2"],"e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496253820930,"score":81.13646},{"pmid":32363253,"pmcid":"PMC7194060","title":"SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease.","text":["SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease.","Kidney Int Rep","Trujillo, Hernando","Caravaca-Fontan, Fernando","Sevillano, Angel","Gutierrez, Eduardo","Caro, Jara","Gutierrez, Elena","Yuste, Claudia","Andres, Amado","Praga, Manuel","32363253"],"journal":"Kidney Int Rep","authors":["Trujillo, Hernando","Caravaca-Fontan, Fernando","Sevillano, Angel","Gutierrez, Eduardo","Caro, Jara","Gutierrez, Elena","Yuste, Claudia","Andres, Amado","Praga, Manuel"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363253","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ekir.2020.04.024","keywords":["coronavirus disease 2019","chronic kidney disease","dialysis","infectious diseases","renal transplantation"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496053542912,"score":71.52777},{"pmid":32405437,"pmcid":"PMC7218361","title":"Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic.","text":["Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic.","Chronic Dis Transl Med","Li, Juan","Li, Shuang-Xi","Zhao, Li-Fang","Kong, De-Liang","Guo, Zhi-Yong","32405437"],"journal":"Chronic Dis Transl Med","authors":["Li, Juan","Li, Shuang-Xi","Zhao, Li-Fang","Kong, De-Liang","Guo, Zhi-Yong"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405437","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cdtm.2020.05.001","keywords":["coronavirus disease 2019","chronic kidney disease","management","novel coronavirus"],"topics":["Prevention"],"weight":1,"_version_":1666802845433724928,"score":71.29927},{"pmid":32429038,"title":"Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.","text":["Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.","The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients.","Trop Med Infect Dis","Oyelade, Tope","Alqahtani, Jaber","Canciani, Gabriele","32429038"],"abstract":["The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients."],"journal":"Trop Med Infect Dis","authors":["Oyelade, Tope","Alqahtani, Jaber","Canciani, Gabriele"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429038","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/tropicalmed5020080","keywords":["covid-19","sars-cov-2","alcohol-related liver disease","chronic kidney disease","cirrhosis","hepatitis b and c","necrosis","nonalcoholic steatohepatitis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667342288360046593,"score":68.455124}]}